Unlock 30% off global market reports with code ONLINE30 – get insights on tariff changes, macro trends, and global economic shifts.
What is the forecasted revenue size of the ticagrelor industry by 2029?
The ticagrelor market size has grown strongly in recent years. It will grow from $1.79 billion in 2024 to $1.93 billion in 2025 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historic period can be attributed to increasing prevalence of cardiovascular diseases, rising aging population, growing awareness of heart health, expansion of pharmaceutical research, and rising incidence of acute coronary syndrome.
The ticagrelor market size is expected to see strong growth in the next few years. It will grow to $2.57 billion in 2029 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to increasing adoption of personalized medicine, growing healthcare expenditure, rising demand for minimally invasive treatments, increasing focus on preventive cardiology, and government initiatives for cardiac care. Major trends in the forecast period include the development of personalized medicine, the introduction of generic ticagrelor, the integration of artificial intelligence in drug development, the development of next-generation antiplatelet drugs, and a focus on patient compliance through fixed-dose combinations.
Download Your Free Sample PDF:
Which industry-specific innovations are acting as key drivers for the ticagrelor market?
The increasing prevalence of cardiovascular diseases is expected to propel the growth of the ticagrelor market going forward. Cardiovascular diseases refer to a group of disorders affecting the heart and blood vessels, including conditions such as coronary heart disease, heart failure, stroke, and hypertension. The increasing prevalence of cardiovascular diseases is primarily attributed to poor diet, as the excessive consumption of saturated fats, trans fats, added sugars, and sodium contributes to high blood pressure, obesity, and elevated cholesterol levels, all of which are major risk factors for heart-related conditions. Ticagrelor helps in treating cardiovascular diseases by preventing platelet aggregation, reducing the risk of blood clots. It improves patient outcomes by lowering the chances of heart attacks and strokes, especially in high-risk individuals. For instance, in January 2024, according to the American Heart Association, a US-based nonprofit organization, the age-adjusted death rate from cardiovascular disease rose to 233.3 per 100,000 in 2022, marking a 4.0% increase from 224.4 per 100,000 in 2021. Therefore, the increasing prevalence of cardiovascular diseases is driving the growth of the ticagrelor market.
Which segment currently leads the ticagrelor market in terms of revenue share?
The ticagrelor market covered in this report is segmented –
1) By Type: 90 mg Tablet, 60 mg Tablet
2) By Drug Class: Antiplatelet Agents, Antithrombotic Agents
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
4) By Application: Acute Coronary Syndrome, Myocardial Infarction, Stroke Prevention, Other Applications
5) By End User: Hospitals And Clinics, Ambulatory Centers, Other End Users
Subsegments:
1) By 90 Mg Tablet: Standard 90 Mg Ticagrelor Tablet, Extended-Release 90 Mg Ticagrelor Tablet
2) By 60 Mg Tablet: Standard 60 Mg Ticagrelor Tablet, Extended-Release 60 Mg Ticagrelor Tablet
View The Full Market Report:
Which sustainability trends are emerging in the ticagrelor market?
Major companies operating in the ticagrelor market are focusing on obtaining regulatory approvals to expand product indications, increase market access, and strengthen their competitive positioning. Regulatory approvals refer to the official permission granted by government authorities to market and sell a product, ensuring it meets safety, efficacy, and quality standards. For instance, in May 2025, Alembic Pharmaceuticals Ltd., an India-based pharmaceutical company, received an abbreviated new drug application (ANDA) from the US Food & Drug Administration (USFDA) for its generic ticagrelor tablets 90 mg and tentative approval for the 60 mg strength. These tablets are used to reduce the risk of cardiovascular events that work by inhibiting platelet aggregation, thereby preventing the formation of blood clots.
Who are the top competitors in the global ticagrelor market?
Major companies operating in the ticagrelor market are AstraZeneca PLC, Merck KGaA, Boehringer Ingelheim International GmbH, Sun Pharmaceutical Industries Limited, Dr. Reddy’s Laboratories Limited, Cadila Pharmaceuticals Limited, Alkem Laboratories, Alembic Pharmaceuticals Limited, CCL Pharmaceuticals, Neuland Laboratories, Jiangxi Synergy Pharmaceutical Co. Ltd., Leeford Healthcare Limited, Scimplify, JAMP Pharma Corporation, Actoverco Pharmaceutical Company, CTX Lifesciences Private Limited, DM Pharma, Hema Pharmaceuticals Pvt. Ltd., Chia-Tai Tianqing Pharmaceutical Group Co. Ltd., Biophar Lifesciences Pvt. Ltd., PhaseBio Pharmaceuticals Inc.
What regional dynamics are shaping the future of the global ticagrelor market?
North America was the largest region in the ticagrelor market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ticagrelor market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
How Can Companies Use The Ticagrelor Market Report to Drive Business Results?
This report provides actionable insights tailored for business use—not academic analysis. Companies can leverage the data to:
• Time market entry or expansion using growth forecasts and CAGR trends.
• Develop competitive products by tracking key technology shifts and user preferences.
• Tailor regional strategies with in-depth geographic data and local market dynamics.
• Benchmark and plan partnerships using competitive landscape insights.
Purchase The Report And Get A Swift Delivery:
Need Customized Data On Ticagrelor Market?
For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you're entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
Request Customized Data:
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Comments
Post a Comment